- Condition: Multiple Sclerosis
Interventions: Drug: PR Fampridine; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Conditions: Urinary Incontinence; Multiple Sclerosis
Interventions: Biological: OnabotulinumtoxinA; Drug: Placebo (Normal Saline); OnabotulinumtoxinA
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Condition: Type 1 Diabetes
Intervention: Device: Pump suspension
Sponsors: In Home Closed Loop Study Group; In Home Closed Loop Study Group; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Statin; Drug: Ace Inhibitor; Drug: Placebo; Drug: Combination therapy
Sponsors: Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Juvenile Diabetes Research Foundation; Diabetes UK; British Heart Foundation; Pfizer; The University of Western Australia; The Hospital for Sick Children; University of Oxford; St Thomas' Hospital, London
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Systemic Lupus Erythematosus
Intervention: Drug: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Behavioral: Exercise
Sponsors: Capital District Health Authority, Canada; Capital District Health Authority, Canada
Not yet recruiting - verified February 2012 - Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type-1 Diabetes
Intervention: Device: Dual Hormone closed-loop system
Sponsors: Institut de Recherches Cliniques de Montreal; Institut de Recherches Cliniques de Montreal; McGill University Center for Intelligent Machines; Montreal Children's Hospital
Recruiting - verified January 2012 - Conditions: Multiple Sclerosis; Fatigue
Interventions: Drug: Testosterone undecanoate; Drug: placebo
Sponsors: Health Sciences Centre, Winnipeg, Manitoba; Health Sciences Centre, Winnipeg, Manitoba; University of Manitoba; Consortium of Multiple Sclerosis Centers; Manitoba Medical Service Foundation
Not yet recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Intervention: Biological: Adalimumab
Sponsors: Abbott; Abbott
Recruiting - verified April 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis; Post-traumatic Arthritis; Ununited Humeral Head Fracture; Irreducible 3- and 4-part Proximal Humeral Fractures; Avascular Necrosis
Intervention: Device: Trabecular Metal Humeral Stem
Sponsors: Zimmer, Inc.; Zimmer, Inc.
Recruiting - verified April 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis; Post-traumatic Arthritis; Ununited Humeral Head Fracture; Irreducible 3-and 4-part Proximal Humeral Fractures; Avascular Necrosis; Gross Rotator Cuff Deficiency; Failed Total Shoulder Arthroplasty (Both Glenoid and Humeral Components Require Revision
Intervention: Device: Trabecular Metal Reverse Shoulder System
Sponsors: Zimmer, Inc.; Zimmer, Inc.
Recruiting - verified May 2012 - Condition: Cutaneous Lupus Erythematosus
Interventions: Drug: PD-0360324; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 3mg; Drug: Ofatumumab 30mg; Drug: Ofatumumab 60mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis, Arthritis, Juvenile Rheumatoid
Intervention: Drug: Tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Idiopathic Thrombocytopenic Purpura; Thrombocytopenia; Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP); Thrombocytopenic Purpura
Interventions: Drug: romiplostim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Elan Pharmaceuticals
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: ISIS CRP Rx or Placebo
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified March 2012 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: BI 10773
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Proteinuria; Idiopathic Membranous Nephropathy
Interventions: Drug: Repository Corticotropin Injection; Drug: Placebo
Sponsors: Questcor Pharmaceuticals, Inc.; Questcor Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Secukinumab (75 mg); Drug: Secukinumab (150 mg); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Cutaneous Lupus; Lupus
Interventions: Drug: AMG 557; Drug: AMG 557 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: BMS-945429 Placebo; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Biological: BMS-945429; Drug: Methotrexate; Drug: Methotrexate; Drug: Methotrexate Placebo; Drug: Methotrexate; Drug: Adalimumab Placebo; Drug: Adalimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: PF-04171327; Drug: prednisone; Other: prednisone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention: Other: Observational study
Sponsors: Canadian Research & Education in Arthritis; Canadian Research & Education in Arthritis; Abbott
Recruiting - verified November 2011 - Condition: Rheumatoid Arthritis
Interventions: Biological: secukinumab; Biological: secukinumab; Biological: placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Intervention: Other: Transition Coordinator
Sponsors: University of Western Ontario, Canada; University of Western Ontario, Canada; Juvenile Diabetes Research Foundation
Not yet recruiting - verified March 2012 - Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: etanercept
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: etanercept
Sponsors: Amgen; Amgen
Recruiting - verified March 2012 - Conditions: Degenerative Joint Disease; Congenital Deformity; Arthritis; Osteoarthritis; Rheumatoid Arthritis
Interventions: Device: Augment(tm) Injectable Bone Graft; Procedure: Autologous bone graft
Sponsors: BioMimetic Therapeutics; BioMimetic Therapeutics
Recruiting - verified July 2011 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: TcLand Expression S.A.; TcLand Expression S.A.; Premier Research Group plc; Theradis pharma; Medpharmgene Inc.
Recruiting - verified October 2011 - Condition: Type 1 Diabetes
Interventions: Device: Simultaneous RT-CGM and Pump Initiation; Device: Delayed Initiation of RT-CGM
Sponsors: Children's Hospital of Eastern Ontario; Children's Hospital of Eastern Ontario; JDRF Canadian Clinical Trial Network
Recruiting - verified November 2011 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Sifalimumab; Drug: Sifalimumab; Drug: Sifalimumab; Drug: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified January 2012 - Condition: Graves Ophthalmopathy
Interventions: Drug: Botulinum Toxin Type A; Drug: Saline injection
Sponsors: University of Toronto; University of Toronto; Allergan
Not yet recruiting - verified December 2010 - Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Fostamatinib and placebo injections; Drug: Adalimumab and placebo of fostamatinib; Drug: Placebo of fostamatinib, fostamatinib, and placebo injections
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Multiple Sclerosis Relapse
Interventions: Drug: Teriflunomide (HMR1726); Drug: Matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: Fostamatinib; Drug: Fostamatinib; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: placebo; Drug: tocilizumab [RoActemra/Actemra]; Drug: tocilizumab [RoActemra/Actemra]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified January 2012 - Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: CNTO 148 (Golimumab); Biological: CNTO 148 (golimumab) or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Schering-Plough (Ireland) Company
Recruiting - verified May 2012 - Conditions: Churg-Strauss Syndrome; Giant Cell Arteritis; Granulomatosis With Polyangiitis (Wegener's); Microscopic Polyangiitis; Polyarteritis Nodosa; Takayasu's Arteritis
Intervention:
Sponsors: Boston University; Boston University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Office of Rare Diseases (ORD); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Conditions: Oxidative Stress; Inflammation; Aging; Dementia; Pain
Intervention: Dietary Supplement: secoisolariciresinol diglucoside
Sponsors: University of Saskatchewan; University of Saskatchewan; Saskatchewan Health Research Foundation
Recruiting - verified October 2011 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo every 2 weeks; Drug: Placebo every 4 weeks
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: Part 1: Etoricoxib 60 mg; Drug: Part 1: Etoricoxib 90 mg; Drug: Part 2: Etoricoxib 60 mg; Drug: Part 2: Etoricoxib 90 mg; Drug: Part 1: Placebo to Etoricoxib 60 mg; Drug: Part 1: Placebo to Etoricoxib 90 mg; Drug: Part 2: Placebo to Etoricoxib 60 mg; Drug: Part 2: Placebo to Etoricoxib 90 mg
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: fostamatinib; Drug: fostamatinib; Drug: placebo
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012 - Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: ocrelizumab; Drug: Placebo; Drug: methylprednisolone
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Early Rheumatoid Arthritis
Interventions: Biological: adalimumab; Drug: methotrexate
Sponsors: Abbott; Abbott
Recruiting - verified May 2012 - Conditions: Minimal Change Disease (MCD); Membranous Nephropathy; Glomerulosclerosis, Focal Segmental
Intervention:
Sponsors: University of Michigan; University of Michigan; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); The NephCure Foundation
Recruiting - verified March 2012 - Condition: Systemic Lupus Erythematosus
Intervention: Other: Standard care plus Yoga
Sponsors: McGill University Health Center; McGill University Health Center
Recruiting - verified July 2011 - Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept; Drug: Methotrexate; Drug: Abatacept Placebo; Drug: Methotrexate Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: Arthritis, Rheumatoid
Interventions: Biological: adalimumab; Drug: Methotrexate
Sponsors: Abbott; Abbott; Mount Sinai Hospital, Canada
Recruiting - verified December 2011 - Conditions: Multiple Sclerosis; MS
Interventions: Device: RebiSmart™; Device: RebiSmart™
Sponsors: Merck KGaA; Merck KGaA; EMD Inc., Canada
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Abbott; Abbott; University Health Network, Toronto
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: University of British Columbia; University of British Columbia; Canadian Institutes of Health Research (CIHR); Canada Foundation for Innovation; Genome British Columbia
Recruiting - verified January 2012 - Condition: Type 1 Diabetes Mellitus
Interventions: Drug: DiaPep277; Drug: Placebo
Sponsors: Andromeda Biotech Ltd.; Andromeda Biotech Ltd.
Recruiting - verified September 2011 - Condition: SLE
Intervention: Drug: MEDI-570
Sponsors: MedImmune LLC; MedImmune LLC; AstraZeneca
Recruiting - verified January 2012 - Condition: Lupus Arthritis
Interventions: Drug: Laquinimod; Drug: Laquinimod; Other: Placebo
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-293987; Drug: Placebo
Sponsors: Actelion; Actelion
Recruiting - verified April 2012 - Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Recruiting - verified January 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: SAR153191 (REGN88); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis; Regeneron Pharmaceuticals
Recruiting - verified May 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Interferon β 1a; Drug: DAC HYP
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified March 2012 - Conditions: Autoantibody Positive; Non-diabetic Relatives at Risk for Type 1 Diabetes; High Risk; Impaired Glucose Tolerance
Intervention: Drug: Teplizumab
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified February 2012 - Condition: Active Rheumatoid Arthritis
Intervention: Drug: SBI-087
Sponsors: Pfizer; Pfizer; Emergent Product Development Seattle LLC
Recruiting - verified April 2012 - Conditions: Purpura, Thrombocytopenic, Idiopathic; Immune Thrombocytopenic Purpura
Interventions: Drug: eltrombopag; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012 - Condition: Myasthenia Gravis
Interventions: Drug: Methotrexate; Other: Placebo
Sponsors: University of Kansas; University of Kansas; Food and Drug Administration (FDA)
Recruiting - verified March 2012 - Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
Sponsors: Bayer; Bayer
Recruiting - verified May 2012 - Condition: Systemic Lupus Erythematosus
Intervention: Drug: AMG 557
Sponsors: Amgen; Amgen
Recruiting - verified August 2011 - Conditions: Arthritis, Rheumatoid; Spondylitis, Ankylosing; Arthritis, Psoriatic
Intervention:
Sponsors: Janssen Inc.; Janssen Inc.
Recruiting - verified May 2012 - Conditions: Crohn Disease; Arthritis, Rheumatoid
Intervention:
Sponsors: Janssen Inc.; Janssen Inc.
Recruiting - verified May 2012 - Conditions: Clinically Isolated Syndromes; Early Single Relapse of Multiple Sclerosis
Interventions: Drug: Apo-Minocycline; Drug: Placebo Comparator
Sponsors: University of Calgary; Dr. Luanne Metz; Multiple Sclerosis Society of Canada
Recruiting - verified March 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Teriflunomide (HMR1726); Drug: Placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Conditions: Type 1 Diabetes; Pregnancy
Intervention:
Sponsors: University of Alberta; University of Alberta
Recruiting - verified September 2011 - Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: IGIV3I Grifols 10%
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified April 2012 - Conditions: Osteoarthritis; Rheumatoid Arthritis
Intervention: Behavioral: Exercise
Sponsors: University of Alberta; University of Alberta; Alberta Heritage Foundation for Medical Research; Canadian Institutes of Health Research (CIHR)
Recruiting - verified April 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Procedure: Islet transplant
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Procedure: Islet transplant; Drug: Belatacept; Drug: Basiliximab; Drug: Mycophenolate Mofetil
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Conditions: Arthritis, Rheumatoid; Osteoarthritis
Interventions: Drug: celecoxib; Drug: Ibuprofen; Drug: Naproxen
Sponsors: Pfizer; Pfizer; The Cleveland Clinic
Recruiting - verified May 2012 - Condition: Temporal Arteritis
Intervention:
Sponsors: Boston University; Peter A. Merkel; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Condition: Churg-Strauss Syndrome
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Conditions: Granulomatosis With Polyangiitis; Microscopic Polyangiitis; Wegener's
Intervention:
Sponsors: Boston University; Boston University; Office of Rare Diseases (ORD); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Rare Diseases Clinical Research Network
Recruiting - verified February 2012 - Condition: Myasthenia Gravis
Interventions: Procedure: thymectomy; Drug: prednisone
Sponsors: University of Alabama at Birmingham; Gary Cutter, PhD; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified October 2011 - Conditions: Systemic Lupus Erythematosus; Antiphospholipid Syndrome
Intervention:
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012
 |
Join Clinical Trials in Surprise,Arizona |
